Brief: Aura Biosciences Announces Positive Interim Phase 2 Safety And Efficacy Data Of Belzupacap Sarotalocan (Bel-Sar) For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma With Suprachoroidal Administration
16/02/2023 12:40
Feb 16 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2 SAFETY
AND
EFFICACY DATA OF BELZUPACAP SAROTALOCAN (BEL-SAR) FOR THE
FIRST-LINE TREATMENT OF PATIENTS WITH EARLY-STAGE CHOROIDAL
MELANOMA WITH SUPRACHOROIDAL ADMINISTRATION
Source text for Eikon: ID:nBw4CnndMa
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs